Methoxsalen Market
The market for Methoxsalen was estimated at $226 million in 2024; it is anticipated to increase to $339 million by 2030, with projections indicating growth to around $476 million by 2035.
Global Methoxsalen Market Outlook
Revenue, 2024
Forecast, 2034
CAGR, 2025 - 2034
The Methoxsalen industry revenue is expected to be around $241.9 million in 2025 and expected to showcase growth with 7.0% CAGR between 2025 and 2034. The escalating CAGR of Methoxsalen reinforces its increasing significance in the medical arena. The primary factors propelling this expansion include an upsurge in instances of skin disorders such as vitiligo and psoriasis, an augmenting ageing populace susceptible to these ailments and the effective functionality of this drug in the UV therapy process. As Methoxsalen garners more recognition for its critical therapeutic role, its relevance in the pharmaceutical sector is anticipated to persist, evolving in tandem with advances in dermatological treatments and research breakthroughs.
Methoxsalen, a psoralen compound that is prominently employed in PUVA (psoralen with ultraviolet A) therapy, exhibits its vital role in the management of serious skin diseases. Its distinct mechanism of action involves intertwining with the DNA of the skin cells upon activation by UVA light, preventing abnormal cell growth, and thus facilitating improved skin condition. Major applications of Methoxsalen extend beyond treating psoriasis and vitiligo, to include eczema and somes of skin lymphomas.
Market Key Insights
- The Methoxsalen market is projected to grow from $226.1 million in 2024 to $445 million in 2034. This represents a CAGR of 7%, reflecting rising demand across Psoriasis Treatment, Eczema Therapy and Vitiligo Management.
- Novartis AG, Pfizer Inc., GlaxoSmithKline plc are among the leading players in this market, shaping its competitive landscape.
- U.S. and Germany are the top markets within the Methoxsalen market and are expected to observe the growth CAGR of 4.5% to 6.7% between 2024 and 2030.
- Emerging markets including Brazil, South Korea and UAE are expected to observe highest growth with CAGR ranging between 8.0% to 9.7%.
- Shift In Treatment Approaches transition is widening cross-selling opportunities across the Methoxsalen industry ecosystem, helping companies drive stronger adoption of their full product portfolio. This ecosystem pull-through is projected to add $3 million to Methoxsalen industry product sales in 2025.
- The Methoxsalen market is set to add $219 million between 2024 and 2034, with manufacturer targeting Oncology & Pharmaceuticals Application Areas projected to gain a larger market share.
- With Increasing incidences of skin disorders, and Advancements in phototherapy treatment, Methoxsalen market to expand 97% between 2024 and 2034.